Linked Life Data

10395192

Source:http://linkedlifedata.com/resource/pubmed/id/10395192

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1999-7-14
pubmed:abstractText
Complex metabolic diseases like type 2 diabetes (noninsulin-dependent diabetes) and obesity present a difficult challenge to pharmaceutical companies in their attempts to develop new therapies. The polygenic nature of these diseases and the influence of nongenetic factors make it difficult to identify the most critical molecular processes to target for drug development. Transgenic animal models provide an approach to evaluate specific sites in metabolic and hormone signalling pathways under physiologic (as opposed to in vitro) conditions. The advantages and limitations of using transgenic animals in drug development will be covered and an overview of recent information from transgenic studies relevant to type 2 diabetes and obesity will be given.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0954-6820
pubmed:author
pubmed:issnType
Print
pubmed:volume
245
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
627-35
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Genetically engineered mice in drug development.
pubmed:affiliation
Bayer Corporation, West Haven, CT 06516-4175, USA.
pubmed:publicationType
Journal Article, Review